Clinical Trial Results

Showing: All studies [change]
Condition: Breast Cancer Location: Wyoming 21 trials found
New Search
Filter
Trial Phase
Study Type
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NAINTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
E-Mindfulness Approaches for Living After Breast Cancer
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
An Internet-based Program to Help Cancer Survivors Manage Pain
NAINTERVENTIONAL Fort Smith, Arkansas +4 more
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NAINTERVENTIONAL Fairbanks, Alaska +4 more
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
N/AOBSERVATIONAL Anchorage, Alaska +4 more
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Mobile Health for Adherence in Breast Cancer Patients
NAINTERVENTIONAL Fairbanks, Alaska +4 more
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
PHASE3INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
PHASE2INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Galleri® in the Medicare Population.
NAINTERVENTIONAL Fort Smith, Arkansas +4 more
RECRUITING
Increasing Germline Genetic Testing for Patients With Cancer
NAINTERVENTIONAL Los Angeles, California +4 more
RECRUITING
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
PHASE2INTERVENTIONAL Basking Ridge, New Jersey +4 more
RECRUITING
Pan Tumor Rollover Study
PHASE2INTERVENTIONAL Huntsville, Alabama +4 more
RECRUITING
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
PHASE2INTERVENTIONAL San Carlos, California +4 more
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
PHASE2, PHASE3INTERVENTIONAL Hot Springs, Arkansas +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type